(SeaPRwire) – By: Christian Brooks
Shanghai, June 5, 2026 – LongBio Pharma lists on HKEX. It issued shares at HK$96.06 each. Opened at HK$144.30. Market cap hits HK$10.7 billion. Qiming Venture Partners invested in B2 and C rounds. Holds 4.27% before IPO. Founded 2020, focuses on allergic/autoimmune biopharma. Team has rich experience. Dr. Sun Naichao, co-founder, key inventor of omalizumab. LP-003 better than omalizumab in CSU. LP-005 is bifunctional complement protein. Listing is lab to commercial milestone.
Author bio: Christian Brooks, prominent financial and business lead commentator.